GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Devyser Diagnostics AB (OSTO:DVYSR) » Definitions » Debt-to-Asset

Devyser Diagnostics AB (OSTO:DVYSR) Debt-to-Asset : 0.13 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Devyser Diagnostics AB Debt-to-Asset?

Devyser Diagnostics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr13.7 Mil. Devyser Diagnostics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr45.4 Mil. Devyser Diagnostics AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was kr473.8 Mil. Devyser Diagnostics AB's debt to asset for the quarter that ended in Dec. 2024 was 0.12.


Devyser Diagnostics AB Debt-to-Asset Historical Data

The historical data trend for Devyser Diagnostics AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Devyser Diagnostics AB Debt-to-Asset Chart

Devyser Diagnostics AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial 0.29 0.03 0.04 0.15 0.13

Devyser Diagnostics AB Quarterly Data
Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.14 0.13 0.13 0.13

Competitive Comparison of Devyser Diagnostics AB's Debt-to-Asset

For the Diagnostics & Research subindustry, Devyser Diagnostics AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Devyser Diagnostics AB's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Devyser Diagnostics AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Devyser Diagnostics AB's Debt-to-Asset falls into.


;
;

Devyser Diagnostics AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Devyser Diagnostics AB's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Devyser Diagnostics AB's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Devyser Diagnostics AB  (OSTO:DVYSR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Devyser Diagnostics AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Devyser Diagnostics AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Devyser Diagnostics AB Business Description

Traded in Other Exchanges
Address
Instrumentvagen 19, Hagersten, SWE, 126 53
Devyser Diagnostics AB develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. The products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.

Devyser Diagnostics AB Headlines

No Headlines